NCT04113993 - Bazedoxifene -Treatment for Women With Schizophrenia | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

October 7, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

SchizophreniaSchizophreniform DisordersSchizo Affective Disorder

Interventions

DRUG

Bazedoxifene Acetate

Oral Bazedoxifene dosed at 40 mg daily for 12 weeks

DRUG

Placebo

Identically packaged placebo capsule daily

Trial Locations (1)

RECRUITING

Monash Alfred Psychiatry Research Centre, Melbourne